Investment Rating - The report maintains a "Recommended" rating for the companies involved in the chromatography industry, particularly focusing on domestic innovation and market potential [57]. Core Insights - The chromatography industry is experiencing significant growth, driven by the increasing demand in the biopharmaceutical sector, which accounts for 80% of the chromatography medium applications [22][37]. - The global biopharmaceutical market is projected to grow from approximately $503 billion in 2023 to $892 billion by 2028, with a compound annual growth rate (CAGR) of 9.5%-12.5% [30]. - Domestic biopharmaceutical market growth is robust, with projections indicating an increase from ¥262.2 billion in 2018 to ¥534.8 billion in 2024, reflecting a CAGR of 12.61% [37]. Market Overview - The chromatography industry includes core consumables, instruments, and software services, with a complete product system that plays a crucial role in drug purification and analysis [15][16]. - The chromatography equipment market is expected to see significant growth, with the small molecule liquid chromatography system market projected to grow from $3.6 billion in 2021 to $7.7 billion by 2026, representing a CAGR of 16.7% [40]. - The chromatography medium market in China is expected to grow from ¥112 billion in 2023 to over ¥203 billion by 2026, with a CAGR of 21.92% [47]. Key Segments - **Innovative Drugs**: The report highlights the transition from generic to innovative drugs in China, with a focus on companies like BeiGene and Innovent Biologics, which are expected to lead in product pipelines and market share [9][57]. - **Medical Devices**: The report notes a recovery in the bidding for imaging devices and a growing market for home medical devices, driven by government subsidies [61]. - **IVD (In Vitro Diagnostics)**: The report emphasizes the acceleration of domestic replacement in the luminescence sector, with companies like Mindray and New Industries leading the charge [59][60]. Industry Trends - The report identifies a shift towards domestic production and innovation in the chromatography sector, with local companies making significant strides in filling the gaps left by international firms [53][56]. - The biopharmaceutical sector's increasing reliance on chromatography technology for drug development and production is expected to drive demand for high-quality chromatography products [22][37]. - The report also discusses the impact of national policies aimed at promoting domestic high-end scientific instruments, which are expected to further enhance the growth of the chromatography industry [53].

Core Viewpoint - The medical services sector experienced a rise of 1.37% on October 24, with Bid Medicine leading the gains, while the Shanghai Composite Index closed at 3950.31, up 0.71% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with Bid Medicine (688073) closing at 76.99, up 8.21% with a trading volume of 11,600 and a transaction value of 87.11 million [1]. - Other notable performers included Haoyuan Medicine (688131) at 85.07, up 6.30%, and Innovation Medical (002173) at 23.42, up 4.93% [1]. - The overall trading volume and transaction values for the sector indicated strong investor interest, with a total of 2.79 billion net inflow from major funds [2]. Group 2: Fund Flow Analysis - Major funds showed a net inflow of 2.79 billion, while retail investors experienced a net outflow of 826.12 million [2]. - Specific stocks like Innovation Medical (002173) had a net inflow of 2.20 billion from major funds, despite a net outflow of 1.43 billion from retail investors [3]. - Other stocks such as Kanglong Chemical (300759) and Meian Health (002044) also showed mixed fund flows, with significant net inflows from major funds but outflows from retail investors [3].

Core Viewpoint - The CRO index experienced a strong performance on October 24, with an intraday increase of 2.01% [1] Group 1: Index Performance - The CRO index saw a day-on-day increase of 2.01% [1] Group 2: Component Stocks - Most component stocks rose, with Boten Co., Ltd. leading the gains at 5.40% [1] - Jiuzhou Pharmaceutical increased by 4.52% [1] - Bid Pharma rose by 4.31% [1] - Haoyuan Pharmaceutical followed with a 4.15% increase [1] - Kanglong Chemical achieved a rise of 3.59% [1]

Market Overview - On October 23, the medical services sector rose by 0.19% compared to the previous trading day, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 71.15, up 5.27% with a trading volume of 11,500 lots and a transaction value of 799.13 million [1] - ST Zhongzhu (600568) closed at 2.02, up 5.21% with a trading volume of 400,000 lots and a transaction value of 794.03 million [1] - Other notable gainers include *ST Biology (000504) at 9.50, up 2.48%, and Kanglong Chemical (300759) at 31.44, up 1.55% [1] Top Losers in Medical Services - Haitai Bio (300683) closed at 32.06, down 7.15% with a trading volume of 136,900 lots and a transaction value of 440 million [2] - Innovative Medical (002173) closed at 22.32, down 5.10% with a trading volume of 639,200 lots and a transaction value of 143.2 million [2] - Other significant decliners include Chengda Pharmaceutical (301201) at 32.70, down 3.77%, and Heyuan Bio (688238) at 7.49, down 2.60% [2] Capital Flow Analysis - On the same day, the medical services sector experienced a net outflow of 637 million from institutional investors, while retail investors saw a net inflow of 723 million [2][3] - The overall capital flow indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2][3] Individual Stock Capital Flow - For Aier Eye Hospital (300015), there was a net outflow of 20.59 million from institutional investors, while retail investors contributed a net inflow of 231,940 [3] - Kanglong Chemical (300759) saw a net inflow of 17.04 million from institutional investors, but a net outflow of 2.59 million from retail investors [3] - Bid Pharma (688073) had a net inflow of 1.08 million from institutional investors, while retail investors contributed a net inflow of 504,580 [3]

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a year-to-date increase of 43.25% and a recent uptick of 2.37% on October 23, 2023, indicating strong market interest and performance [1]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the early stages of new drug development, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, reflecting a 41.60% increase compared to the previous period [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - The top circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Agricultural Bank Medical Health Stock, with changes in their holdings indicating active institutional interest [3].

Automotive Industry - The core point of the report highlights the impressive performance of the Chinese automotive industry in the first three quarters of 2025, with strong growth in new energy vehicles (NEVs) [3][4] - In the first three quarters of 2025, production and sales of NEVs exceeded 11.24 million units, representing a year-on-year growth of 35.2% and 34.9% respectively, with a penetration rate of 46.1% [4] - In September 2025, NEV production and sales reached 1.617 million and 1.604 million units, showing a month-on-month increase of 16.3% and 15%, and a year-on-year increase of 23.7% and 24.6% [4] - The export volume of automobiles in the first three quarters of 2025 increased by 14.8% year-on-year, with a total export of 4.95 million vehicles [4] - The report suggests focusing on leading companies in the NEV supply chain and those with overseas market presence, as the increasing penetration rate of NEVs will drive the collaborative development of the entire industry chain [4][5] Investment Recommendations - The report indicates that the automotive sector is experiencing a resonance phase between new product cycles and technological advancements, particularly in smart driving and smart cockpit technologies, which are expected to drive continuous sales growth [5] - Continuous policy support for automotive consumption and the rising penetration rate of NEVs provide a broad market space for vehicle manufacturers [5] - In the components sector, the rapid increase in the penetration of smart components such as smart cockpits and electric drive systems is expected to benefit related companies [5] - The report maintains an "overweight" rating for the automotive industry, recommending attention to quality companies in the sector, such as Shuanghuan Transmission and Beite Technology [5] New Materials - The report notes a slight increase of 0.05% in the rare earth magnetic materials industry, outperforming the benchmark by 2.27 percentage points [7] - The prices of rare earth concentrates have accelerated their decline, with specific price drops reported for various rare earth minerals [9] - The report highlights the need to monitor the demand side closely, as the market's just-in-time transactions are primarily driven by basic needs, with expectations for demand to improve in the coming months [10] Medical Services - The report indicates a decline of 2.48% in the pharmaceutical and biological sector, with the medical services sub-sector experiencing a significant drop of 5.21% [11][12] - The current PE ratio for the medical services sector is 34.96, with a recent decrease of 1.96 from the previous week [13][14] - The report emphasizes the potential of ADC (Antibody-Drug Conjugates) and CDMO (Contract Development and Manufacturing Organization) in the innovative drug sector, projecting significant growth in the ADC outsourcing market [15][16] - The report maintains a "buy" rating for the medical services industry, recommending attention to high-growth companies and those with improving expectations, such as WuXi AppTec and Aier Eye Hospital [17] ETF Market Overview - As of October 17, 2025, there are 1,328 ETFs in the Shanghai and Shenzhen markets, with a total asset management scale of 55,264.48 billion [19] - The report notes that the average weekly change in shares for stock ETFs was an increase of 27.63 million shares, with significant increases in bank and brokerage ETFs [20] - The report recommends focusing on the automotive, coal, and agriculture sectors within the PB-ROE framework for ETF rotation strategies, highlighting the potential for these sectors to outperform [24]

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a 43.27% increase, indicating strong market performance and investor interest [1][2]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the early stages of new drug development, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, up 41.60% year-on-year [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which is the second-largest shareholder with 4.2526 million shares, and Agricultural Bank of China Medical Health Stock, which increased its holdings by 17.75% [2].

Company Overview - Bid Pharma's stock increased by 5.2%, reaching 68.14 CNY per share, with a trading volume of 16.89 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 6.193 billion CNY [1] - The company, established on April 27, 2007, and listed on October 11, 2022, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Fund Holdings - According to data, one fund under Xinda Australia, the Xinao Small and Medium Cap Mixed A (610004), holds a significant position in Bid Pharma, with 227,200 shares, accounting for 6.11% of the fund's net value, making it the fourth-largest holding [2] - The fund has achieved a floating profit of approximately 765,800 CNY today [2] - The Xinao Small and Medium Cap Mixed A fund was established on December 1, 2009, with a current size of 216 million CNY, yielding 22.89% year-to-date and ranking 3,418 out of 8,234 in its category [2] Fund Manager Performance - The fund manager, Zeng Guofu, has a tenure of 17 years and 87 days, with a total fund size of 481 million CNY, achieving a best return of 109.1% and a worst return of -57.43% during his tenure [3] - Co-manager Li Diandian has been in position for 1 year and 6 days, managing a fund size of 570 million CNY, with a best return of 35.83% and a worst return of 14.26% during his tenure [3]

Core Points - Bid Pharma's stock price decreased by 10.07% this week, closing at 64.77 yuan, with a market capitalization of 5.886 billion yuan [1] - The company plans to conduct foreign exchange hedging to mitigate currency fluctuation risks, with a maximum contract value of 600 million yuan [2][4] - Bid Pharma's initial public offering raised approximately 1.335 billion yuan, with plans to use up to 200 million yuan of idle funds for cash management [3][4] Company Announcements - Bid Pharma intends to engage in foreign exchange hedging, with a limit of 600 million yuan for any single trading day [2][4] - The company has approved the use of up to 200 million yuan of idle raised funds for cash management, focusing on low-risk, liquid financial products [3][4]

Group 1 - The core point of the news is that Shanghai Bid Pharmaceutical Co., Ltd. is taking measures to manage foreign exchange risks and optimize the use of idle funds from its initial public offering [1][2][3] Group 2 - On October 16, 2023, Bid Pharmaceutical's stock closed at 66.4 yuan, down 3.02%, with a turnover rate of 1.99% and a trading volume of 8,585 lots, amounting to 58.1291 million yuan [1] - The main capital flow on October 16 showed a net outflow of 184,400 yuan from institutional investors, accounting for 0.32% of the total trading volume, while retail investors had a net outflow of 1.066 million yuan, representing 1.83% of the total [1][3] - The company plans to conduct foreign exchange hedging activities with a maximum contract value of 600 million yuan, using its own funds, and has established a foreign exchange risk management system [1][3] - The company intends to use up to 200 million yuan of temporarily idle raised funds for cash management, investing in low-risk, liquid, and principal-protected financial products [2][3]